Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra rapid formulation insulin lispro - Eli Lilly and Company

Next Previous
Drug Profile

Ultra rapid formulation insulin lispro - Eli Lilly and Company

Alternative Names: insulin lispro-aabc injection; Liumjev™; LY-900014; Lyumjev; Lyumjev U-100; Lyumjev U-200; rapid acting insulin - Eli Lilly and Company; Ultra rapid lispro; URLi

Latest Information Update: 10 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 10 Jan 2025 Phase III in Type-2 diabetes mellitus (Combination therapy) is ongoing in USA
  • 10 Jan 2025 Phase III in Type-I diabetes mellitus (In adolescents, In children, In infants) is ongoing in Israel and Canada
  • 10 Jan 2025 Phase III in Type-I diabetes mellitus (In adolescents, In children, In infants) is ongoing in Russia and China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top